v3.26.3
Fair Value Measurements
9 Months Ended
Sep. 30, 2026
Fair Value Measurements  
Fair Value Measurements

4. Fair Value Measurements

In accordance with ASC 820 (Fair Value Measurements and Disclosures), the Company uses various inputs to measure the fair value of liabilities related to certain embedded conversion feature associated with its warrant liability, convertible debt, share payable, and contingent payable to Cognate BioServices on a recurring basis to determine the fair value of these liabilities. The Company has also elected the fair value option (the “FVO”) for certain financial instruments, such as convertible notes.

ASC 820 establishes a hierarchy categorizing inputs into three levels used to measure and disclose fair value. The hierarchy gives the highest priority to quoted prices available in active markets and the lowest priority to unobservable inputs. An explanation of each level in the hierarchy is described below:

Level 1 - Unadjusted quoted prices in active markets for identical instruments that are accessible by the Company on the measurement date.

Level 2 - Quoted prices in markets that are not active or inputs which are either directly or indirectly observable.

Level 3 - Unobservable inputs for the instrument requiring the development of assumptions by the Company.

The following table classifies the Company’s liabilities measured at fair value on a recurring basis into the fair value hierarchy as of September 30, 2026 and December 31, 2025 (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Fair value measured at September 30, 2026

​

  ​ ​ ​

​

​

  ​ ​ ​

Quoted prices in active

  ​ ​ ​

Significant other

  ​ ​ ​

Significant

​

  ​ ​ ​

Fair value at

​

markets

​

observable inputs

​

unobservable inputs

​

​

September 30, 2026

  ​ ​ ​

(Level 1)

  ​ ​ ​

(Level 2)

  ​ ​ ​

(Level 3)

Convertible notes at fair value

​

$

42,894

​

 

—

​

 

—

​

$

42,894

Share payable

​

​

393

​

​

—

​

​

—

​

​

393

Total fair value

​

$

43,287

​

$

—

​

$

—

​

$

43,287

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Fair value measured at December 31, 2025

​

  ​ ​ ​

​

​

  ​ ​ ​

Quoted prices in active

  ​ ​ ​

Significant other

  ​ ​ ​

Significant

​

​

Fair value at

​

markets

​

observable inputs

​

unobservable inputs

​

  ​ ​ ​

December 31, 2025

  ​ ​ ​

(Level 1)

  ​ ​ ​

(Level 2)

  ​ ​ ​

(Level 3)

Contingent payable derivative liability

​

$

9,416

​

​

—

​

​

—

​

$

9,416

Convertible notes at fair value

​

​

37,276

​

​

—

​

​

—

​

​

37,276

Share payable

 

​

373

​

 

—

​

 

—

​

 

373

Total fair value

​

$

47,065

​

$

—

​

$

—

​

$

47,065

​

There were no transfers between Level 1, 2 or 3 during the three-month period ended September 30, 2026.

The following table presents changes in Level 3 liabilities measured at fair value for the nine-month period ended September 30, 2026. Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long- dated volatilities) inputs (in thousands).

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Convertible

​

​

​

​

​

Contingent Payable

​

Share

​

Notes

​

​

​

​

  ​ ​ ​

Derivative Liability

  ​ ​ ​

Payable

  ​ ​ ​

At Fair Value

  ​ ​ ​

Total

Balance - January 1, 2026

​

$

9,416

​

$

373

​

$

37,276

​

$

47,065

Additional share payable

​

​

—

​

​

849

​

​

—

​

​

849

Issuance of convertible notes at fair value

​

​

—

​

​

—

​

​

16,164

​

​

16,164

Redemption of share payable

​

​

—

​

​

(702)

​

​

—

​

​

(702)

Additions from debt extinguishment

​

​

—

​

​

—

​

​

6,381

​

​

6,381

Debt repayment

​

​

—

​

​

—

​

​

(500)

​

​

(500)

Debt conversion

​

​

—

​

​

—

​

​

(15,075)

​

​

(15,075)

Change in fair value

​

​

(9,416)

(1)

​

(127)

​

​

(1,352)

​

​

(10,895)

Balance - September 30, 2026

​

$

—

​

$

393

​

$

42,894

​

$

43,287

(1)The fair value of the contingent payable derivative liability was reduced to zero as of September 30, 2026, because the underlying performance condition required for payment is not probable prior to the note’s expiration on May 21, 2026.

A summary of the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring the Company’s share payable that are categorized within Level 3 of the fair value hierarchy on the initial issuance date during the nine months ended September 30, 2026 and 2025, and remearured as of September 30, 2026 and December 31, 2025 are as follows. The liability relates to the remaining redemption feature which, like the convertible notes at fair value, includes discount factors that are unobservable inputs and proprietary in nature.

​

​

​

​

​

​

​

​

​

​

​

Share Payable

​

​

​

For the nine months ended

​

​

​

September 30, 

​

​

  ​ ​ ​

2026

  ​ ​ ​

2025

​

Strike price

​

$

0.15

​

$

0.24

​

Contractual term (years)

​

 

0.09

 

​

0.09

​

Volatility (annual)

​

 

53

%  

​

64

%

Risk-free rate

​

 

3.9

%  

​

4.3

%

Dividend yield (per share)

​

 

0

%  

​

0

%

​

​

​

​

​

​

​

​

​

​

  ​ ​ ​

As of September 30, 2026

  ​ ​ ​

As of December 31, 2025

 

​

​

Share Payable

​

Share Payable

 

Strike price

​

$

0.15

​

$

0.22

​

Contractual term (years)

​

 

0.04

​

 

0.05

​

Volatility (annual)

​

 

52

%  

 

64

%

Risk-free rate

​

 

4.0

%  

 

3.7

%

Dividend yield (per share)

​

 

0

%  

 

0

%

​